Abuse liability assessment of neuroprotectants

Annals of the New York Academy of Sciences

Volumn 890, Issue , 1999, Pages 515-525

  Klein, Michael ^a   Calderon, Silvia ^a   Hayes, Belinda ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; DIZOCILPINE; EXCITATORY AMINO ACID RECEPTOR; GLUTAMIC ACID; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; PHENCYCLIDINE;

BEHAVIOR DISORDER; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; DATA BASE; DISCRIMINATIVE STIMULUS; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; HYSTERIA; INSTRUMENTAL CONDITIONING; NERVE DEGENERATION; NONHUMAN; REINFORCEMENT; SYNAPTIC TRANSMISSION;

ANIMALIA;

EID: 0033426878     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb08033.x     Document Type: Conference Paper

References (22)

1. 1. Controlled Substances Act (CSA), as amended February 15, 1996, Title 21, Food and Drugs, Chapter 13 - Drug Abuse Prevention and Control.
2. 2. Testing Drugs for Physical Dependence Potential and Abuse Liability. 1984. National Institute on Drug Abuse (NIDA) Research Monograph Series 52, Department of Health and Human Services, National Institute on Drug Abuse, GPO, Washington, DC.
3. 3. The Convention on Psychotropic Substances, United Nations, Vienna, February 21, 1971, text in document E/CONF. 58/6.
4. 4. The Single Convention on Narcotic Drugs, 1961, United Nations, New York, March 30, 1961.
5. 5. Leshner, A. I. 1997. Addiction is a brain disease. Sci. 278: 457.
6. 6. Nestler, E.J. & G.K. Aghajanian. 1997. Molecular and cellular basis of addiction. Science 278: 58-63.
7. 9-THC and smoked marijuana in humans. Psychopharmacology 107: 255-262.
8. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA 95: 8268-8273.
9. 9. Grant, K.A., G. Colombo, J. Grant & M.A. Rooawski. 1996. Dizolcilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology 35(12): 1709-1719.
10. 10. Radant, A.D., T.A. Bowdle, D.S. Cowley, E.D. Kharasch & P.P. Roy-Byrne. 1998. Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology 19(5): 434-444.
11. 11. Malhotra, A.K., D.A. Pinals, C.M. Adler, I. Elman, A. Clifton, D. Pickar & A. Breier. 1997. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropharmacology 17(3): 141-150.
12. 12. Javitt, D.C., H. Sershen, A. Hashim & A. Lajtha. 1997. Reversal of phencycline-induced hyperaclivity by glycine and the clycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 17: 202-204.
13. 13. Balster, R. 1991. Drug abuse potential evaluation in animals. Br. J. Addict. 86: 1549-1558.
14. 14. Van Berckel, B.N.M., C. Lipsch, S. Timp, C. Gispen-de Wied, H. Wynne, J.M. van Ree & R.S. Kahn. 1997. Behavioral and neuroendocrine effects of partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology 16(5): 317-324.
15. 11C-raclopride in normal human subjects. Neuropsychopharmacology 18(1): 18-25.
16. 2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology 18(1): 57-62.
17. 17. Malhotra, A.K., D.A. Pinals, H. Weingartner, K. Sirocco, C.D. Missar, D. Pickar & A. Breier. 1998. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14(5): 301-307.
18. 18. Sams-Dodd, F. 1998. Effects of continuous d-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 19(1): 18-25.
19. 19. Doppenberg, E.M.R., S.C. Choi & R. Bullock. 1997. Clinical trials in traumatic brain injury. What can we learn from previous studies? Ann. N.Y. Acad. Sci. 825: 305-322.
20. 20. Beardsley, P.M., R.L. Balster & L.S. Harris. 1986. Dependence on tetrahydrocannabinol in rhesus monkeys. J. Pharmacol. Exp. Ther. 239: 311-319.
21. 21. Slifer, B.L., R.L. Balster & W.L. Woolverton. 1984. Behavioral dependence produced by continuous phencyclidine infusion in rhesus monkeys. J. Pharmacol. Exp. Ther. 230: 399-406.
22. 22. Meeting of the FDA Drug Abuse Advisory Committee, Subcommittee on Abuse Liability Assessment, Food and Drug Administration, Rockville, Maryland, January 1990.